PT  - JOURNAL ARTICLE
AU  - Andrzej Jarynowski
AU  - Alexander Semenov
AU  - Mikołaj Kamiński
AU  - Vitaly Belik
TI  - Mild Adverse Events of Sputnik V Vaccine Extracted from Russian Language Telegram Posts via BERT Deep Learning Model
AID  - 10.1101/2021.06.14.21258875
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.14.21258875
4099  - http://medrxiv.org/content/early/2021/06/22/2021.06.14.21258875.short
4100  - http://medrxiv.org/content/early/2021/06/22/2021.06.14.21258875.full
AB  - Background There is a limited amount of data on the COVID-19 vector vaccine Gam-COVID-Vac (Sputnik V) safety profile. Previous infodemiology studies showed that social media discourse could be analyzed to assess the most concerning adverse events (AE) caused by drugs.Objective We aimed to investigate mild AEs of Sputnik V based on a participatory trial conducted on Telegram in the Russian language. We compared AEs extracted from Telegram with other limited databases on Sputnik V and other COVID-19 vaccines. We explored symptom co-occurrence patterns and determined how counts of administered doses, age, gender, and sequence of shots could confound the reporting of AEs.Materials and Methods We collected a unique dataset consisting of 11,515 self-reported Sputnik V vaccine AEs posted on the Telegram group, and we utilized natural language processing methods to extract AEs. Specifically, we performed multi-label classifications using the deep neural language model BERT “DeepPavlov”, which we pre-trained on a Russian language corpus and applied to the Telegram messages. The resulting AUC score was 0.991. We chose symptom classes that represented the following AEs: fever, pain, chills, fatigue, nausea/vomiting, headache, insomnia, lymph node enlargement, erythema, pruritus, swelling, and diarrhea.Results The results of the retrospective analysis showed that females reported more AEs than males (1.2-fold, P<.001). In addition, there were more AEs from the first dose than from the second dose (1.13-fold, P<.001), and the number of AEs decreased with age (β = .05 per year, P<.001). The results also showed that Sputnik V AEs were more similar to other vector vaccines (132 units) compared with mRNA ones (241 units) according to the average Euclidean distance between the vectors of AE frequencies. Elderly Telegram users reported significantly more (5.6-fold on average) systemic AEs than their peers, according to the results of the phase III clinical trials published in The Lancet. However, the AEs reported in Telegram posts were consistent (Pearson correlation r=.94, P=.02) with those reported in the Argentinian post-marketing AE registry.Conclusion After receiving the Sputnik V vaccination, Telegram users complained about pain (47%), fever (47%), fatigue (34%), and headache (25%). The results showed that the AE profile of Sputnik V was comparable with other COVID-19 vaccines. Examining the sentinel properties of participatory trials (which is subject to self-reporting biases) could still provide meaningful information about pharmaceutics, especially if only a limited amount of information on AEs is provided by producers.Competing Interest StatementMK received remuneration for performing vaccinations against COVID-19 in primary care. The vaccinations did not involve Sputnik V. Funding Statementno external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data contained no personal information, and the analysis was performed according to the Terms of Service of the platform. Our analysis was completely anonymous and performed in aggregated form. No possible harm to Telegram users was identified. Therefore, the study did not require ethical committee approval. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data available upon request